个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Yi[1,2,3,4] ; Zhou Hu[5] ; Jiang Zhongxing[6] ; Wu Dengshu[7] ; Zhuang Junling[8] ; Li Wei[9] ; Jiang Qian[10] ; Wang Xiuli[11] ; Huang Jinwen[12] ; Zhu Huanling[13] ; Yang Linhua[14] ; Du Xin[15] ; Li Fei[16] ; Xia Ruixiang[17] ; Zhang Feng[18] ; Hu Jianda[19] ; Li Yan[20] ; Hu Yu[21] ; Liu Jing[22] ; Jin Chenghao[23] ; Sun Kai[24] ; Zhou Zeping[25] ; Wu Liqing[26] ; Yu Wenjuan[1,2,3,4] ; Jin Jie[1,2,3,4,*1] ;
机构： [1]Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China. [2]Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, P.R. China. [3]Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, P.R. China. [4]Zhejiang University Cancer Center, Hangzhou, P.R. China. [5]Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, P.R. China. [6]Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China. [7]Department of Hematology, Xiangya Hospital, Central South University, Changsha, P.R. China. [8]Department of Hematology, Peking Union Medical College Hospital (Dongdan Campus), Beijing, P.R. China. [9]Department of Hematology, Cancer Center, The First Hospital of Jilin University, Changchun, P.R. China. [10]Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell, Beijing, P.R. China. [11]Department of Oncology Hematology, The Second Hospital of Jilin University, Changchun, P.R. China. [12]Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China. [13]Department of Hematology, West China Hospital, Sichuan University, Chengdu, P.R. China. [14]Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, P.R. China. [15]Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, P.R. China. [16]Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, P.R. China. [17]Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, P.R. China. [18]Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China. [19]Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, P.R. China. [20]Department of Hematopathology, The First Hospital of China Medical University, Shenyang, P.R. China. [21]Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China. [22]Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, P.R. China. [23]Department of Hematology, Jiangxi Provincial People's Hospital, Nanchang, P.R. China. [24]Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, P.R. China. [25]Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, P.R. China. [26]Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, P.R. China.
出处：
DOI： 10.1002/ajh.26709
ISSN：

摘要：
Myelofibrosis (MF) is associated with several constitutional symptoms. Currently, there are few therapeutic options for MF. Jaktinib, a novel, small-molecule inhibitor of JAK, is currently being studied for its potential to treat MF. This phase 2 trial investigated efficacy and safety of jaktinib in the treatment of MF patients. The primary end point was the proportion of patients with ≥35% reduction in spleen volume (SVR35, proportion of patients with ≥35% reduction in spleen volume) at week 24. The secondary end points included improvement of anemia, rates of symptom response, and safety profile. Between January 8, 2019 and August 29, 2020, 118 patients were recruited and treated with either jaktinib 100 mg BID or 200 mg QD. At week 24, 54.8% (34/62) of patients in the 100 mg BID group and 31.3% (15/48) in the 200 mg QD group achieved SVR35 (p = .0199). Jaktinib treatment increased hemoglobin level to ≥20 g/L in 35.6% (21/59) of patients with hemoglobin ≤100 g/L at baseline. The proportion of patients who achieved a ≥50% improvement in total symptom score at week 24 was 69.6% (39/56) in the BID group and 57.5% (23/40) in the QD group. The most common ≥ grade 3 hematological treatment-emergent adverse events (TEAEs; ≥ 10%) were anemia (100 mg BID: 24.2%, 200 mg QD: 28.8%), thrombocytopenia (16.7%, 11.5%), and neutropenia (3.0%, 11.5%). All non-hematological TEAEs were mild. These results indicate that jaktinib can shrink the spleen, improve anemia, and other clinical symptoms with good tolerability.© 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

基金：
Suzhou Zelgen Biopharmaceuticals Co., Ltd; The Key Research and Development Program of Zhejiang Province, Grant/Award Number: 2021C03123
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 2 区 血液学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 血液学
JCR分区：
出版当年[2022]版：
Q1 HEMATOLOGY
最新[2023]版：
Q1 HEMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China. [2]Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, P.R. China. [3]Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, P.R. China. [4]Zhejiang University Cancer Center, Hangzhou, P.R. China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China. [2]Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, P.R. China. [3]Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, P.R. China. [4]Zhejiang University Cancer Center, Hangzhou, P.R. China. [*1]The First Affiliated Hospital, School of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou 310003, P.R. China.
推荐引用方式(GB/T 7714)：
Zhang Yi,Zhou Hu,Jiang Zhongxing,et al.Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial[J].AMERICAN JOURNAL OF HEMATOLOGY.2022,97(12):1510-1519.doi:10.1002/ajh.26709.
APA：
Zhang Yi,Zhou Hu,Jiang Zhongxing,Wu Dengshu,Zhuang Junling...&Jin Jie.(2022).Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.AMERICAN JOURNAL OF HEMATOLOGY,97,(12)
MLA：
Zhang Yi,et al."Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial".AMERICAN JOURNAL OF HEMATOLOGY 97..12(2022):1510-1519

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号